BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu Y, Zhang C, Jiang K, Werner J, Bazhin AV, D'Haese JG. The Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives. Front Oncol 2020;10:621937. [PMID: 33520728 DOI: 10.3389/fonc.2020.621937] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
Number Citing Articles
1 Hrabák P, Kalousová M, Krechler T, Zima T. Pancreatic stellate cells - rising stars in pancreatic pathologies. Physiol Res 2021. [DOI: 10.33549//physiolres.934783] [Reference Citation Analysis]
2 Herring B, Jang S, Whitt J, Goliwas K, Aburjania Z, Dudeja V, Ren B, Berry J, Bibb J, Frost A, Chen H, Rose JB, Jaskula-Sztul R. Ex Vivo Modeling of Human Neuroendocrine Tumors in Tissue Surrogates. Front Endocrinol (Lausanne) 2021;12:710009. [PMID: 35002949 DOI: 10.3389/fendo.2021.710009] [Reference Citation Analysis]
3 Magni L, Bouazzi R, Heredero Olmedilla H, Petersen PSS, Tozzi M, Novak I. The P2X7 Receptor Stimulates IL-6 Release from Pancreatic Stellate Cells and Tocilizumab Prevents Activation of STAT3 in Pancreatic Cancer Cells. Cells 2021;10:1928. [PMID: 34440697 DOI: 10.3390/cells10081928] [Reference Citation Analysis]
4 Zhang Z, Zhang H, Liu T, Chen T, Wang D, Tang D. Heterogeneous Pancreatic Stellate Cells Are Powerful Contributors to the Malignant Progression of Pancreatic Cancer. Front Cell Dev Biol 2021;9:783617. [PMID: 34988078 DOI: 10.3389/fcell.2021.783617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Plesca I, Benešová I, Beer C, Sommer U, Müller L, Wehner R, Heiduk M, Aust D, Baretton G, Bachmann MP, Feldmann A, Weitz J, Seifert L, Seifert AM, Schmitz M. Clinical Significance of Tumor-Infiltrating Conventional and Plasmacytoid Dendritic Cells in Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2022;14:1216. [PMID: 35267524 DOI: 10.3390/cancers14051216] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Edwards P, Kang BW, Chau I. Targeting the Stroma in the Management of Pancreatic Cancer. Front Oncol 2021;11:691185. [PMID: 34336679 DOI: 10.3389/fonc.2021.691185] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Tarannum M, Vivero-Escoto JL. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment. Adv Drug Deliv Rev 2022;187:114357. [PMID: 35605679 DOI: 10.1016/j.addr.2022.114357] [Reference Citation Analysis]
8 Li J, Kang R, Tang D. Cellular and molecular mechanisms of perineural invasion of pancreatic ductal adenocarcinoma. Cancer Commun (Lond) 2021;41:642-60. [PMID: 34264020 DOI: 10.1002/cac2.12188] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Waldenmaier M, Seibold T, Seufferlein T, Eiseler T. Pancreatic Cancer Small Extracellular Vesicles (Exosomes): A Tale of Short- and Long-Distance Communication. Cancers (Basel) 2021;13:4844. [PMID: 34638330 DOI: 10.3390/cancers13194844] [Reference Citation Analysis]
10 Modica C, Olivero M, Zuppini F, Milan M, Basilico C, Vigna E. HGF/MET Axis Induces Tumor Secretion of Tenascin-C and Promotes Stromal Rewiring in Pancreatic Cancer. Cancers (Basel) 2021;13:3519. [PMID: 34298732 DOI: 10.3390/cancers13143519] [Reference Citation Analysis]
11 Desbois M, Wang Y. Cancer-associated fibroblasts: Key players in shaping the tumor immune microenvironment. Immunol Rev 2021;302:241-58. [PMID: 34075584 DOI: 10.1111/imr.12982] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]